Skin Cancer

Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.

The inaugural workshop explored skin cancer care from prevention and diagnosis through systemic therapy, radiation, and multidisciplinary management.

The expanded indication makes Ameluz with RhodoLED the first FDA-approved photodynamic therapy for the treatment of a skin cancer.

The final session of the Cutaneous Oncology Workshop explored advances in systemic therapy, management of immunotherapy-related skin reactions, and the role of radiation.

At the Dermatology Times NP/PA Cutaneous Oncology Workshop in Tampa, Florida, Amit Om, MD, outlined why field-directed therapy is increasingly favored over lesion-directed treatment for actinic keratosis.

Attendees put technique into practice during an interactive suturing session led by Tristan Hasbargen, PA-C, using individual kits and real-world clinical examples.

At the Cutaneous Oncology Workshop, faculty explored lesion recognition, surgical decision-making, risk stratification, and the evolving role of molecular testing.

Faculty at the Dermatology Times Cutaneous Oncology Workshop addressed real-world questions on mole mapping, biopsy decisions, oral photoprotection, and actinic keratosis treatment.

In the morning session, Experts highlighted evolving photoprotection strategies, field-directed treatment of actinic keratoses, hereditary cancer risk, and practical dermoscopy pearls for APPs.

As chair of the new Dermatology Times NP/PA Connect Cutaneous Oncology Workshop, Tristan Hasbargen, PA-C, discusses the program's curriculum and goals live in Tampa, Florida.

Dermatology Times kicks off its first Cutaneous Oncology Workshop, bringing APPs and experts together for practical skin cancer education.

Advanced practice providers will gather September 12 for a full-day program covering skin cancer prevention, diagnosis, staging, treatment, and procedural skills.

Joshua Arbesman, MD, explains how tailored sun-safety advice balances melanoma risk, aging goals, and quality of life in all types of patients.

Joshua Arbesman, MD, explains how to promote smarter sun habits, educate on melanoma-risk timelines, ease guilt, and answer sunscreen fears fueled by social media.

Shawn Demehri, MD, PhD, discussed immunomodulatory and antigen-directed immunotherapy approaches for skin cancer prevention in a recent Dermatology Times interview.

Shawn Demehri, MD, PhD, discusses a calcipotriene/5-FU combination immunotherapy for field cancerization and its potential in organ transplant recipients.

Shawn Demehri, MD, PhD, discussed a topical combination immunotherapy being studied for skin cancer prevention in high-risk patients.

Experts map referral pathways and team-based immunotherapy care for advanced cutaneous squamous cell carcinoma, tackling toxicity and follow-up gaps.

Experts weigh checkpoint inhibitors for advanced cutaneous squamous cell carcinoma, highlighting real-world safety, immunotherapy referrals, and where cosibelimab may belong.

Stephanie Kauffman, chief executive officer of the Melanoma Research Alliance, discussed funding strategy, early career researcher support, and melanoma prevention in a recent Dermatology Times interview.

Multidisciplinary experts rethink advanced cutaneous squamous cell carcinoma care, weighing immunotherapy options, trial data limits, adverse events, and smoother dermatology-oncology referrals.

The latest DermView custom video series explored how molecular tools are reshaping management decisions in cutaneous squamous cell carcinoma.

Stephanie Kauffman, CEO of the Melanoma Research Alliance, discussed the organization's research priorities as it approaches 20 years of advancing melanoma research.

Goran Mićević, MD, PhD, joined Christopher Bunick, MD, PhD, to discuss phase 3 findings showing an individualized mRNA neoantigen therapy improved outcomes with checkpoint blockade in resected melanoma.

Meta-analysis suggests vitiligo links to lower skin cancer rates, with significantly reduced squamous cell carcinoma; phototherapy shows higher estimates but remains inconclusive.